News Pharma Industry

China is out to strangle India’s bulk drug makers. The government needs to heed the industry’s SOS.


Synopsis

For thousands of units making bulk drugs, or raw materials used to make medicines, there is hardly any incentive to be in the business. As they lose ground to an aggressive Chinese campaign to dump cheaper substitutes, there are multiple issues causing more damage – half-hearted policymaking, a myopic user industry that falls for the cheaper options and shrewd price manoeuvring.

Ajit Kamath is a distraught man. Two decades ago, the turnaround specialist with a bank was reviewing a sick manufacturing unit in Hyderabad that had everything going for it, but an antiquated rule related to loans had sunk it to bankruptcy. Kamath had two choices — either tell the unit to wind up or breathe new life into it. He took a leap of faith. He quit his bank job and took charge of the sick unit. Backed by friends, he marshalled funds,

  • GIFT ARTICLE
  • FONT SIZE
  • SAVE
  • PRINT
  • COMMENT

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

FREEDOM OFFER

Get Flat 25% Off

ON ET PRIME MEMBERSHIP

Get Offer

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise



Source link